Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in psychedelics, named chair of Reset Pharmaceuticals’ Scientific Advisory Board NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) — Reset Pharmaceuticals, Inc. (Reset Pharma) a privately-held biotechnology company…


Previous articleAwakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline
Next articleMindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company